NORVIR (ritonavir) by AbbVie is [see microbiology ( ) ] . First approved in 1996.
Drug data last refreshed 16h ago · AI intelligence enriched 2mo ago
NORVIR (ritonavir) is an oral protease inhibitor solution approved in 1996 for HIV treatment. It works by inhibiting HIV protease, preventing viral replication and reducing viral load in infected patients. Ritonavir is now primarily used as a pharmacokinetic booster in combination antiretroviral regimens rather than as a standalone therapeutic agent.
Declining revenue and minimal Part D claims indicate a mature, contracted franchise with reduced commercial team investment and limited growth opportunities.
[see Microbiology ( ) ] .
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Safety and Effectiveness of Giving Indinavir, Ritonavir, Stavudine, and Lamivudine to HIV-Infected Patients Who Have Never Received Anti-HIV Drugs
The Effectiveness of Ritonavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients
Fortovase (Saquinavir) Given With Low-Dose Ritonavir, Zidovudine, and Lamivudine to HIV-Positive Pregnant Women During and After Pregnancy and to Their Newborns
Safety of AMD070 When Administered Alone or Boosted With Low-Dose Ritonavir in HIV Uninfected Men
A Randomized Trial of the Efficacy and Safety of a Strategy of Starting With Nelfinavir Versus Ritonavir Added to Background Antiretroviral (AR) Nucleoside Therapy in HIV-Infected Individuals With CD4+ Cell Counts Less Than or Equal to 200/mm3
Worked on NORVIR at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moNORVIR offers minimal career growth potential; positions available focus on defensive strategies, cost management, and supply chain optimization rather than growth marketing or innovation. This is a legacy portfolio assignment suitable for professionals seeking stable, operational roles in mature drug management.